恩替卡韦治疗乙型肝炎肝衰竭患者临床研究

钟旬华; 袁静; 杨艳; 李炜; 陈晓英

恩替卡韦治疗乙型肝炎肝衰竭患者临床研究

深圳市第三人民医院

详细信息

中图分类号: R575.3;R512.62
计量
- 文章访问数: 2188
- HTML全文浏览量: 8
- PDF下载量: 879
- 被引次数: 0
出版历程
- 出版日期: 2009-05-20

Investigation of the liver failure patients infected with hepatitis B virus treated with entecavir

摘要

摘要: 目的观察恩替卡韦对乙型肝炎肝衰竭患者的疗效与安全性。方法对30例乙型肝炎肝衰竭患者,在支持治疗基础上予以恩替卡韦每天0.5mg口服,观察服药1年后的生存率、肝功能变化、并发症和血清HBVDNA病毒载量,比较治疗组与对照组治疗的疗效与安全性。结果治疗组与对照组治疗1年生存率分别为70%和43%,治疗组生存率显著高于对照组(x2=4.34,P<0.05),治疗组肝功能和血清HBVDNA病毒载量改善明显优于对照组,且安全性良好。结论恩替卡韦能提高乙型肝炎肝衰竭患者的生存率、促进肝功能恢复,安全有效。
- 恩替卡韦 /
- 治疗 /
- 肝衰竭,乙型肝炎
Abstract: Objective To observe the therapeutic effects and its safety of entecavir on the patients of liver failure with hepatitis B virus infection.Methods The treatment group (n=30) were administered 0.5mg entecavir orally once daily based upon basic supportive therapy.The survival rate, liver function, complications and serum HBVDNA viral load 1 year after treatment were observed and compared with that of the matched controls.Results The survival rate in the treatment group and control were 70.00% and 43% respectively and the survival rate of the treatment group was significantly higher than that of the controls (x2=4.34, P<0.05) .The improvement of liver function and serum HBV DNA viral load at undetectable level at 1year after therapy in enticavir treatment group was significantly higher than that of controls.Morbidity of complications in the treatment group with a good drug safety was superior to that in controls.Conclusion Entecavir showed its positive effect and safety on the improvement of the survival rate and the life quality in patients with hepatitis B liver failure.
- entecavir /
- liver failure /
- hepatitis B

HTML全文

参考文献(8)

[1]陈菊梅, 邹正升.重视乙型肝炎肝衰竭的预防和控制[J].传染病信息, 2008, 21 (2) :65-67.

[2]王宇明, 于乐成.乙型肝炎病毒相关肝衰竭的进展:发病机制和治疗[J].肝脏, 2008, 13 (1) :60-518.

[3]Shaw T, Locarnini S.Entecavir for the treatment of chronichepatitis B[J].Expert Rev Anti Infect Ther, 2004, 2 (6) :853-871.

[4]刘磊, 韩涛, 李莹.恩替卡韦治疗乙型肝炎肝硬化48周疗效观察[J].武警医学院学报, 2008, 17 (4) :307-309.

[5]张耀, 郑莎, 王宇明.拉米夫定治疗乙型肝炎病毒相关性肝衰竭疗效的Meta分析[J].第三军医大学学报, 2008, 30 (9) :848-850.

[6]中华医学会感染病学分会肝衰竭与人工肝学组.肝衰竭诊疗指南[J].中华内科杂志, 2006, 45 (12) :1053-1056.

[7]Tenney DJ, Rose RE, Baldick CJ, et al.Two-year assessment of en-tecavir resistance in Lamivudinerefractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substi-tutions present[J].Antimicrob Agents Chemother, 2007, 51:902-911.

[8]毛日成, 张继明, 尹有宽, 等.恩替卡韦耐药乙型肝炎病毒株的出现和消失[J].肝脏, 2007, 12 (3) :171-174.

施引文献

资源附件(0)

访问统计